12:00 AM
Oct 29, 2012
 |  BC Week In Review  |  Company News  |  Other News

Chesapeake PERL, U.S. Department of Defense neurology, biomanufacturing news

DoD's Defense Threat Reduction Agency (DTRA) awarded Chesapeake a contract to develop a recombinant butyrylcholinesterase (BChE) as a nerve agent countermeasure. The contact will fund development and production...

Read the full 126 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >